US · SY · MEDICAL - HEALTHCARE INFORMATION SERVICES
So-Young International Inc. (SY) intrinsic value and stock valuation
$1.65as of 2026-11-21 · Mkt cap 274.23M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
So-Young International Inc. DCF and intrinsic value
InvestorsCraft values SY with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from SY’s statements →
So-Young International Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2016–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.48B | $1.47B | $1.5B | $1.26B | $1.69B |
| Operating income | -$-259.21M | -$-624.49M | -$-61.05M | -$-102.81M | -$-32.57M |
| Net income | -$-235.7M | -$-589.53M | $21.3M | -$-65.55M | -$-8.37M |
| EPSd | -$-1.79M | -$-4.39M | $161.3K | -$-474.86K | -$-60.63K |
| Operating cash flow | -$-105.39M | -$-25.63M | $22.5M | -$-112.87M | $84.3M |
| Capital expenditure | -$-196.62M | -$-62.55M | -$-51.18M | -$-15.71M | -$-45.06M |
| Free cash flow | -$-302.01M | -$-88.18M | -$-28.68M | -$-128.58M | $39.2M |
| Total assets | $2.65B | $2.74B | $3.21B | $3.2B | $3.33B |
| Total debt | $299.9M | $239.9M | $145.8M | $71.3M | $105.9M |
| Net debt | -$-183.3M | -$-347.87M | -$-280.35M | -$-623.16M | -$-1.23B |
| Total equity | $1.67B | $1.96B | $2.56B | $2.61B | $2.52B |
| Cash and short-term investments | $937M | $1.19B | $1.33B | $1.57B | $1.74B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.48B | $1.47B | $1.5B | $1.26B | $1.69B |
| Cost of revenue | $774M | $567.6M | $544.3M | $393.3M | $327.9M |
| Gross profit | $707.9M | $899.1M | $953.7M | $864.6M | $1.36B |
| Research and development expenses | $133.3M | $165M | $203.5M | $235.1M | $286.6M |
| Selling, general and administrative expenses | $833.8M | $818.6M | $811.2M | $732.3M | $1.04B |
| Other expenses | $0.00 | $540M | $0.00 | $0.00 | $65.9M |
| Operating expenses | $967.1M | $1.52B | $1.01B | $967.4M | $1.4B |
| Cost and expenses | $1.74B | $2.09B | $1.56B | $1.36B | $1.73B |
| Interest income | $24.6M | $46.5M | $48.8M | $28.9M | $19.3M |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $57.2M | $46.1M | $46.1M | $47.1M | $30.1M |
| Ebitda | -$-182.19M | -$-38.39M | $54M | -$-39.99M | $63.4M |
| Operating income | -$-259.21M | -$-624.49M | -$-61.05M | -$-102.81M | -$-32.57M |
| Total other income/expenses, net | $19.8M | $36.4M | $68.9M | $15.7M | $16.2M |
| Income before tax | -$-239.4M | -$-588.09M | $7.87M | -$-87.07M | -$-16.41M |
| Income tax expense | -$-770K | -$-910K | -$-18.07M | -$-20.96M | $21.2M |
| Net income | -$-235.7M | -$-589.53M | $21.3M | -$-65.55M | -$-8.37M |
| Weighted average shares outstanding | $131.6M | $134.1M | $133.2M | $138M | $138M |
| Weighted average diluted shares outstanding | $131.6M | $134.2M | $131.9M | $138M | $138M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $937M | $1.19B | $1.33B | $1.57B | $1.74B |
| Net receivables | $209.9M | $226.3M | $80.4M | $170.3M | $110.5M |
| Inventory | $233.5M | $151.8M | $118.9M | $120.5M | $91.8M |
| Total current assets | $1.49B | $1.72B | $1.72B | $1.92B | $2.03B |
| Property, plant and equipment, net | $545.5M | $318.1M | $235.2M | $179.1M | $220.2M |
| Goodwill and intangible assets | $144.9M | $127.3M | $686M | $710M | $734.7M |
| Long-term investments | $274.9M | $280.3M | $261M | $228M | $252.5M |
| Total non-current assets | $1.17B | $1.01B | $1.49B | $1.28B | $1.3B |
| Total assets | $2.65B | $2.74B | $3.21B | $3.2B | $3.33B |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Short-term debt | $116.4M | $114.7M | $59.6M | $50.3M | $43.5M |
| Deferred revenue | $292.6M | $190.4M | $195.2M | $181.7M | $190.3M |
| Total current liabilities | $784.6M | $630.2M | $540.4M | $538M | $712.4M |
| Long-term debt | $183.5M | $125.2M | $86.2M | $21M | $62.4M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | -$-38.58M |
| Total non-current liabilities | $196.9M | $146.2M | $112.8M | $52M | $100.9M |
| Capital lease obligations | $260M | $170.1M | $116M | $71.3M | $105.9M |
| Total liabilities | $981.4M | $776.4M | $653.3M | $590M | $813.3M |
| Common stock | $290K | $290K | $280K | $270K | $270K |
| Retained earnings | -$-1.18B | -$-885.84M | -$-330.17M | -$-346.62M | -$-272.37M |
| Accumulated other comprehensive income (loss) | $59.8M | $31.6M | $52M | $33.1M | -$-63.56M |
| Total equity | $1.67B | $1.96B | $2.56B | $2.61B | $2.52B |
| Total investments | $728.7M | $879.3M | $1.16B | $1.1B | $661.5M |
| Total debt | $299.9M | $239.9M | $145.8M | $71.3M | $105.9M |
| Net debt | -$-183.3M | -$-347.87M | -$-280.35M | -$-623.16M | -$-1.23B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-246.91M | -$-587.18M | $25.9M | -$-66.11M | -$-37.64M |
| Depreciation and amortization | $57.2M | $45.9M | $46.1M | $47.1M | $30.1M |
| Stock-based compensation | $8.92M | $32.7M | $36.3M | $43.3M | $106.2M |
| Change in working capital | -$-26.11M | -$-167.85M | -$-122.44M | -$-195M | -$-164.54M |
| Accounts receivable | $29.7M | -$-61.48M | -$-28.95M | $13.6M | $14.6M |
| Inventory | -$-115.98M | -$-36.75M | -$-2.12M | -$-27.99M | $7.87M |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | -$-158.37M |
| Net cash provided by operating activities | -$-105.39M | -$-25.63M | $22.5M | -$-112.87M | $84.3M |
| Investments in property, plant and equipment | -$-196.62M | -$-62.55M | -$-51.18M | -$-15.71M | -$-45.06M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-97.49M | -$-636.87M |
| Net cash used for investing activities | -$-42.81M | $257M | -$-202.61M | -$-572.21M | $339.8M |
| Common stock issued | $80K | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-15.25M | -$-18.24M | -$-125.62M | -$-15.12M | -$-217.71M |
| Dividends paid | -$-19.03M | -$-43.57M | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-63.7M | -$-21.51M | -$-100.02M | -$-13.59M | -$-216.74M |
| Net change in cash | -$-213.38M | $213.2M | -$-268.26M | -$-642.81M | $198.1M |
| Cash at end of period | $432.6M | $646M | $432.7M | $701M | $1.34B |
| Operating cash flow | -$-105.39M | -$-25.63M | $22.5M | -$-112.87M | $84.3M |
| Capital expenditure | -$-196.62M | -$-62.55M | -$-51.18M | -$-15.71M | -$-45.06M |
| Free cash flow | -$-302.01M | -$-88.18M | -$-28.68M | -$-128.58M | $39.2M |
Line items
Line items
Line items
About So-Young International Inc.
So-Young International Inc. manages a digital platform specializing in medical aesthetics and elective healthcare services, serving customers in the People's Republic of China and globally. This online ecosystem enables users to explore content, share personal experiences regarding medical aesthetic procedures, and book in-person treatments with various medical aesthetic service providers. The platform also offers resources for researching treatment trends, features ratings and reviews of treatment experiences, and publishes blogs under headings like "Beauty Diaries." Beyond cosmetic enhancements, So-Young facilitates reservations for a broader spectrum of healthcare needs, including dermatology, dentistry (with orthodontics), ophthalmology, comprehensive physical examinations, gynecology, human papillomavirus vaccinations, and postnatal support. The company also supplies Software-as-a-Service (SaaS) solutions and provides guidance and training programs to medical service providers. Its offerings extend to internet information and technology advisory, management consulting, and internet culture services. Furthermore, So-Young is involved in the sale of medical equipment, equipment manufacturing, sales, and agency services, as well as microfinance. As of December 31, 2021, its platform had established connections with approximately 8,400 medical aesthetic service providers and an additional 5,000 providers offering other consumption-focused healthcare services. Established in 2013, So-Young International Inc. maintains its corporate headquarters in Beijing, China.
- CEO
- Xing Jin
- Employees
- 2.35K
- Beta
- 2.02
Explore
Frequently asked questions
What is the intrinsic value of So-Young International Inc. (SY)?
So-Young International Inc. (SY) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SY undervalued?
SY trades at a price of $1.65 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.